Drugs / Tenalisib
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03471351 | Jul 2018 → Feb 2019 | classic Hodgkin lymphoma | Rhizen Pharmaceuticals SA | Terminated | No outcome recorded |
| Phase 1 | NCT02690727 | Feb → Mar 2016 | — | Rhizen Pharmaceuticals SA | Completed | No outcome recorded |
| Phase 1 | NCT02567656 | Sep 2015 → Mar 2018 | peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell lymphoma | Rhizen Pharmaceuticals SA | Completed | No outcome recorded |
| Phase 1 | NCT02017613 | Nov 2013 → May 2016 | B-cell non-Hodgkin lymphoma, T-cell non-Hodgkin lymphoma | Rhizen Pharmaceuticals SA | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03770000 | Mar 2019 → May 2021 | T-cell non-Hodgkin lymphoma | Rhizen Pharmaceuticals SA | Completed | No outcome recorded |
| Phase 1/2 | NCT03711604 | Nov 2018 → Mar 2023 | hematopoietic and lymphoid cell neoplasm | Rhizen Pharmaceuticals SA | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06189209 | Mar 2024 → Dec 2026 expected | triple-negative breast carcinoma | Rhizen Pharmaceuticals SA | Recruiting | No outcome recorded |
| Phase 2 | NCT05239910 | Jan 2023 → Dec 2026 | peripheral T-cell lymphoma, not otherwise specified | Rhizen Pharmaceuticals SA | Withdrawn | No outcome recorded |
| Phase 2 | NCT05021900 | Oct 2021 → Mar 2023 | breast cancer | Rhizen Pharmaceuticals SA | Completed | No outcome recorded |
| Phase 2 | NCT04204057 | Nov 2019 → Oct 2020 | B-cell chronic lymphocytic leukemia | Rhizen Pharmaceuticals SA | Completed | No outcome recorded |
| Phase 2 | NCT03711578 | Nov 2018 → Jun 2020 | non-Hodgkin lymphoma | Rhizen Pharmaceuticals SA | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tenalisib | “Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W” NCT03471351 ↗ |
| Known as | RP6530 | “An Open Label, Phase II Study to Evaluate the Efficacy and Safety of Tenalisib (RP6530), Given With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) Therapy for...” NCT05239910 ↗5“Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor” NCT03711578 ↗ “Single agent Tenalisib \[RP6530 (PI3k delta, gamma and SIK3 inhibitor)\]” NCT06189209 ↗ |
| Action | Inhibit | “PI3-kinase p110-gamma subunit inhibitor” CHEMBL4297584 ↗2“PI3-kinase p110-delta subunit inhibitor” CHEMBL4297584 ↗ “a dual PI3K delta/gamma inhibitor” NCT02017613 ↗ |
| Modality | Small molecule | — CHEMBL4297584 ↗ |
| Route | Oral | “RP6530 administered orally” NCT02017613 ↗ |
| Target | PIK3CD | “PI3-kinase p110-delta subunit inhibitor” CHEMBL4297584 ↗ |
| Target | PIK3CG | “PI3-kinase p110-gamma subunit inhibitor” CHEMBL4297584 ↗ |
| Target | SIK3 | “a PI3K δ/γ and SIK3 Inhibitor” NCT05021900 ↗ |